Health related quality of life for men treated for localized prostate cancer with long-term followup.
OBJECTIVE
Men who undergo primary treatment for prostate cancer can expect changes in health related quality of life. Long-term changes after treatment are not yet fully understood. We characterized health related quality of life evolution from baseline to 4 years after treatment.


METHODS
We identified 1,269 men in CaPSURE who underwent primary treatment for clinically localized prostate cancer and completed followup health related quality of life questionnaires for at least 4 years. The men underwent radical prostatectomy, external beam radiotherapy, brachytherapy, combined external beam radiotherapy/brachytherapy or androgen deprivation therapy. Health related quality of life was measured using patient reported questionnaires. Effects of select covariates on quality of life were measured with a multivariate mixed model.


RESULTS
Age at diagnosis, time from treatment and primary treatment were significant predictors of health related quality of life in all domains (p <0.05) except primary treatment on sexual bother. Men who underwent radical prostatectomy experienced the most pronounced worsening urinary function but also had the greatest recovery. All treatments worsened urinary bother, and sexual function and bother. All forms of radiotherapy moderately worsened bowel function and bother after treatment but eventual recovery to baseline was noted.


CONCLUSIONS
Age at diagnosis, time from treatment and primary treatment type affect health related quality of life. Treatment has a greater impact on disease specific than general health related quality of life. All treatments adversely affect urinary and sexual function. Most adverse changes develop immediately after treatment. Recovery occurs mostly within 2 years after treatment with little change beyond 3 years.
Huang
George J
GJ
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Sadetsky
Natalia
N
Penson
David F
DF
D000368:Aged; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000628:therapy*; D011788:Quality of Life; D013997:Time Factors
J Clin Oncol. 2005 Apr 20;23(12):2772-80
15837992
Cancer. 2007 Jun 1;109(11):2239-47
17455209
Urology. 1996 Nov;48(5):773-7
8911524
J Gen Intern Med. 2000 Oct;15(10):694-701
11089712
J Urol. 2007 Jan;177(1):273-8; discussion 278-9
17162062
Lancet. 1997 Mar 29;349(9056):906-10
9093251
Health Econ. 1993 Oct;2(3):217-27
8275167
Cancer. 2002 Feb 1;94(3):862-71
11857323
Cancer. 2001 Jun 15;91(12):2302-14
11413519
J Natl Cancer Inst. 2009 Jun 16;101(12):888-92
19509365
J Urol. 2000 Dec;164(6):1973-7
11061894
J Clin Oncol. 2002 Jan 15;20(2):557-66
11786586
Arch Intern Med. 2007 Oct 8;167(18):1944-50
17923593
Int J Urol. 2009 Jan;16(1):45-8
19120525
N Engl J Med. 2008 Mar 20;358(12):1250-61
18354103
J Urol. 2003 Nov;170(5):1822-7
14532784
J Natl Cancer Inst. 2004 Sep 15;96(18):1358-67
15367568
Med Care. 1998 Jul;36(7):1002-12
9674618
JAMA. 1998 Sep 16;280(11):969-74
9749478
N Engl J Med. 2002 Sep 12;347(11):790-6
12226149
J Clin Oncol. 2003 Mar 15;21(6):1147-54
12637483